

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5954103

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JONATHAN BELK	12/09/2019
RECEIVING PARTY DATA	
Name:	ADIMAB, LLC
Street Address:	7 LUCENT DRIVE
City:	LEBANON
State/Country:	NEW HAMPSHIRE
Postal Code:	03766
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	16711180
PCT Number:	US2019065776
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	brooks.hall2@gilead.com
Correspondent Name:	KITE PHARMA, INC.
Address Line 1:	2400 BROADWAY
Address Line 4:	SANTA MONICA, CALIFORNIA 90404
ATTORNEY DOCKET NUMBER:	K-1074.PC/PF
NAME OF SUBMITTER:	IAN GRISWOLD
SIGNATURE:	/Ian Griswold/
DATE SIGNED:	02/10/2020
Total Attachments: 3	
source=K-1074.PC-PF Adimab Executed Assignment#page1.tif	
source=K-1074.PC-PF Adimab Executed Assignment#page2.tif	
source=K-1074.PC-PF Adimab Executed Assignment#page3.tif	

ASSIGNMENT BY INVENTOR

THIS ASSIGNMENT, made by Jonathan Belk, who has a mailing address at c/o Adimab, LLC, 7 Lucent Drive, Lebanon, NJ 03766.

WHEREAS, Jonathan Belk has invented certain new and useful improvements in CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE, set forth in an application for Letters Patent of the United States, for which Assignors have filed an application for patent both under the Patent Cooperation Treaty (PCT) and in the United States of America concurrently herewith. Where this Assignment is not filed concurrently with the application, the following identifying information may be added after execution:

U.S. Serial No.: 16/711,180 Filing Date: December 11, 2019

PCT Serial No.: PCT/US2019/065776 Filing Date: December 11, 2019

WHEREAS, Jonathan Belk, as part of his employment with Adimab, LLC, for work created within the scope of his employment, assigned all of his rights to Adimab, LLC, a limited liability company organized under and pursuant to the laws of Delaware, having its principal place at 7 Lucent Drive, Lebanon, NJ 03766.

WHEREAS, Adimab, LLC executed a Collaboration Agreement with Kite Pharma, Inc. effective on June 15, 2015, wherein Adimab, LLC (hereinafter referred to as Assignor) assigned all of its rights to Kite Pharma, Inc. (hereinafter referred to as Assignee).

WHEREAS, Kite Pharma, Inc., a Corporation organized under and pursuant to the laws of Delaware having its principal place of business at 2400 Broadway; Santa Monica, California 90404 (hereinafter referred to as Assignee), is desirous of acquiring the entire right, title and interest in and to said inventions and said Application for Letters Patent of the United States, and in and to any Letters Patent of the United States to be obtained therefore and thereon.

NOW, THEREFORE, to all whom it may concern, be it known that for good and sufficient consideration, the receipt of which is hereby acknowledged, Assignor has sold, assigned, transferred and set over, and by these presents does sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions and applications for Letters Patent, and in and to any and all direct and indirect provisionals, national stage applications, divisions, continuations, continuations-in-part, substitutions, and reissues of said application, and any and all Letters Patent in the United States and all foreign countries which may be granted therefore and thereon, and reissues, reexaminations and extensions of said Letters Patent, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted and/or extended, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

AND for the same consideration, Assignor hereby represents and warrants to Assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, except for any rights, titles and/or interests that have arisen to Assignee under law or that have already been transferred to Assignee, Assignor is the sole and lawful owner of the entire right, title and interest in and to the said inventions and application for Letters Patent above-mentioned, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, Assignor hereby covenants and agrees to and with Assignee, its successors, legal representatives and assigns, that Assignor will sign all papers and documents, take all lawful oaths and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of any Letters Patent and applications for Letters Patent for said inventions, without charge to Assignee, its successors, legal representatives and assigns, whenever counsel of Assignee, or counsel of its successors, legal representatives and assigns, shall advise: that any proceeding in connection with said inventions, or said Patent

application for Letters Patent, or any proceeding in connection with any Letters Patent or applications for Letters Patent for said inventions including but not limited to interference proceedings, is lawful and desirable; or, that any division, continuation or continuation-in-part of any application for Letters Patent, or any reissue, reexamination or extension of any Letters Patent, to be obtained thereon, is lawful and desirable.

AND Assignor acknowledges an obligation of assignment of this invention to Assignee at the time the invention was made.

We hereby grant Assignee(s), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

Date: Dec 7th, 2019

Signature: _____

Jonathan Belk

Date: Dec. 9th 2019

Signature: _____

Printed Name: EMIL KRAMLAND
Title: Chief Scientific Officer
Adimab, LLC

Acknowledged by:

Date: December 10, 2019 Signature: _____

Printed Name: Yi-Ming Dammann
Title: Associate General Counsel
Kite Pharma, Inc.